Idiopathic pulmonary fibrosis

BMJ (Online)

Volumn 347, Issue , 2013, Pages

  Dempsey, Owen J ^a   Miller, David ^b  

^a ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; AMBRISENTAN; AMIODARONE; ANTIBIOTIC AGENT; AZATHIOPRINE; BOSENTAN; CORTICOSTEROID; COTRIMOXAZOLE; DIURETIC AGENT; GAMMA INTERFERON; IMATINIB; IMMUNOSUPPRESSIVE AGENT; MACITENTAN; NINTEDANIB; NITROFURANTOIN; OZONE; PIRFENIDONE; PLACEBO; PREDNISOLONE; SILDENAFIL; WARFARIN;

AGE DISTRIBUTION; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ASTHMA; AWARENESS; AXILLA; BRONCHIECTASIS; CHRONIC DISEASE; CHRONIC INFLAMMATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EVALUATION; CLINICAL FEATURE; CLINICAL PRACTICE; COMORBIDITY; CONNECTIVE TISSUE DISEASE; COUGHING; DELAYED DIAGNOSIS; DIFFERENTIAL DIAGNOSIS; DIGITAL CLUBBING; DISEASE CONTROL; DRUG APPROVAL; DRUG COST; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DYSPNEA; EDITORIAL; ENVIRONMENTAL EXPOSURE; FIBROSING ALVEOLITIS; FRAIL ELDERLY; GENERAL PRACTITIONER; HEALTH CARE PERSONNEL; HEALTH SERVICE; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; LUNG ALVEOLUS EPITHELIUM; LUNG BIOPSY; LUNG LOBE; LUNG TRANSPLANTATION; MEDICAL SOCIETY; MEDICATION COMPLIANCE; NAUSEA; ONSET AGE; OXYGEN THERAPY; PALLIATIVE THERAPY; PATIENT CARE; PATIENT REFERRAL; PHASE 3 CLINICAL TRIAL (TOPIC); PHOTOSENSITIVITY; PNEUMONIA; POPULATION RESEARCH; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PULMONARY REHABILITATION; QUALITY OF LIFE; SMOKING; SURVIVAL RATE; THORAX RADIOGRAPHY; TREATMENT OUTCOME; UNITED KINGDOM; UNITED STATES;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CLINICAL TRIALS AS TOPIC; DIAGNOSIS, DIFFERENTIAL; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; PRACTICE GUIDELINES AS TOPIC; PYRIDONES; TREATMENT OUTCOME;

EID: 84888195139     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.f6579     Document Type: Editorial

References (24)

1. Flint A. A treatise on the principles and practice of medicine. Henry C Lea, 1868:193.
2. Bjoraker JA, Ryu JH, Edwin MK, Myers JL, Tazelaar HD, Schroeder DR, et al. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998;157:199-203.
3. Navaratnam V, Fleming KM, West J, Smith CJ, Jenkins RG, Fogarty A, et al. The rising incidence of idiopathic pulmonary fibrosis in the U.K. Thorax 2011;66:462-7.
4. Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006;174:810-6.
5. Nalysnyk L, Cid-Ruzafa J, Rotella P, Esser D. Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature. Eur Respir Rev 2012;21:355-61.
6. National Institute for Health and Care Excellence. Idiopathic pulmonary fibrosis: the diagnosis and management of suspected idiopathic pulmonary fibrosis. 2013. http://guidance.nice.org.uk/CG163.
7. King TE Jr, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet 2011;378:1949-61.
8. National Institute for Health and Care Excellence. Pirfenidone for treating idiopathic pulmonary fibrosis. 2013. http://guidance.nice.org.uk/ta282.
9. Lee JS, McLaughlin S, Collard HR. Comprehensive care of the patient with idiopathic pulmonary fibrosis. Curr Opin Pulm Med. 2011;17:348-54.
10. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183:788-824.
11. Bradley B, Branley HM, Egan JJ, Greaves MS, Hansell DM, Harrison NK, et al. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax 2008;63(suppl 5):v1-58.
12. Cottin V, Cordier JF. Velcro crackles: the key for early diagnosis of idiopathic pulmonary fibrosis? Eur Respir J 2012;40:519-21.
13. Kishaba T, Shimaoka Y, Fukuyama H, Yoshida K, Tanaka M, Yamashiro S, et al. A cohort study of mortality predictors and characteristics of patients with combined pulmonary fibrosis and emphysema. BMJ Open 2012;2:e000988.
14. Dempsey OJ, Kerr KM, Remmen H, Denison AR. How to investigate a patient with suspected interstitial lung disease. BMJ 2010;340:c2843.
15. Williams TJ, Wilson JW. Challenges in pulmonary fibrosis: 7 - novel therapies and lung transplantation. Thorax 2008;63:277-84.
16. Antoniou KM, Margaritopoulos GA, Siafakas NM. Pharmacological treatment of idiopathic pulmonary fibrosis: from the past to the future. Eur Respir Rev 2013;22:281-91.
17. Richeldi L, Davies HR, Ferrara G, Franco F. Corticosteroids for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev 2003;3:CD002880.
18. Spagnolo P, Del Giovane C, Luppi F, Cerri S, Balduzzi S, Walters EH, et al. Non-steroid agents for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev 2010;9:CD003134.
19. Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, Jansen HM, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005;353:2229-42.
20. Richeldi L, Costabel U, Selman M, Kim DS, Hansell DM, Nicholson AG, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 2011;365:1079-87.
21. Shulgina L, Cahn AP, Chilvers ER, Parfrey H, Clark AB, Wilson EC, et al. Treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole: a randomised controlled trial. Thorax 2013;68:155-62.
22. Maher TM. Pirfenidone in idiopathic pulmonary fibrosis. Drugs Today (Barc) 2010;46:473-82.
23. Raghu G, Thickett DR. Pirfenidone for IPF: pro/con debate; the "con" viewpoint. Thorax 2013;68:605-8.
24. Jenkins G. Pirfenidone should be prescribed for patients with idiopathic pulmonary fibrosis. Thorax 2013;68:603-5.